Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00620191Phase 2Completed

Metformin in Amnestic Mild Cognitive Impairment

Role: collaborator

NCT00105105Phase 2Terminated

Mifepristone as Adjunctive Therapy in Alzheimer's Disease

Role: collaborator

NCT00017940Phase 1Completed

Gene Therapy for Alzheimer's Disease Clinical Trial

Role: collaborator

NCT00099710Phase 2Completed

Curcumin in Patients With Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT00024531Phase 2Completed

Lipitor as a Treatment for Alzheimer's Disease

Role: lead

All 5 trials loaded